Key takeaways

  • A skin patch or gel delivers systemic oestrogen. Low-dose vaginal products mainly treat nearby tissues, with minimal bloodstream absorption compared with systemic HRT. NICE
  • For systemic HRT, NICE recommends combined oestrogen and progestogen for people with a uterus, and oestrogen alone after total hysterectomy, with specialist advice for other relevant conditions. NICE
  • Local symptoms can persist during systemic treatment, so both may be considered. NICE recommends review at 3 months and annually afterwards, or earlier for problems; a breast-cancer history requires a separate assessment. NICE

Local versus systemic HRT: what is the practical difference?

Local vs Systemic HRT: What Is the Practical Difference?

Local vaginal oestrogen is intended mainly for genitourinary symptoms such as vaginal dryness, irritation and discomfort; only a small amount is absorbed into the bloodstream compared with systemic HRT. Systemic HRT circulates through the body and may address symptoms such as hot flushes. The routes, benefits, precautions and need for progestogen are not interchangeable.

Does “topical” always mean local?

No. Skin-applied oestrogen patches, sprays and gels are systemic treatments. Low-dose vaginal oestrogen tablets, creams, gels, pessaries or rings are designed primarily to act on vaginal and urinary tissues. By contrast, oestrogen patches, sprays and gels placed on the skin are designed to cross the skin and enter the circulation. They are transdermal, but systemic.

The words describe where the medicine is intended to act, not simply where it is applied. A person comparing two “gels” must still check the active ingredient, strength, application site and product information. Similarly, a vaginal ring can be local or systemic depending on the product; the dosage form alone is not enough.

Which symptoms does each type address?

Local vaginal oestrogen is used for dryness, soreness, irritation and painful sex. NICE menopause guidance describes local absorption with minimal bloodstream exposure compared with systemic HRT.

HealthHub’s Vagifem leaflet shows a vaginal tablet at the tip of a disposable applicator, opposite the push button. Keep hands clean and dry to avoid wetting it. The instructions say to insert the applicator before pressing the button; a click signals release of the tablet. Remove and discard the applicator afterwards. These are product-specific instructions, so check the prescribed leaflet.

Systemic HRT is used when treatment needs to have an effect throughout the body. It may be considered for vasomotor symptoms such as hot flushes and night sweats, and may affect other menopause-associated symptoms and bone health depending on the person’s circumstances. Local vaginal treatment should not be assumed to treat systemic symptoms.

QuestionLocal vaginal oestrogenSystemic HRT
Main treatment reachVaginal and nearby urinary tissuesThroughout the body
Common formsVaginal tablet, cream, pessary or ringOral tablet; skin patch, gel or spray; combined regimens vary
Typical symptom focusGenitourinary symptomsVasomotor and other eligible menopause symptoms
Bloodstream exposureMinimal compared with systemic HRT, but not literally zeroIntended systemic exposure
Can the other type still be needed?Systemic symptoms require separate assessmentPersistent local symptoms may require separate assessment

Why does having a uterus matter for systemic treatment?

A progestogen protects the uterine lining from systemic oestrogen stimulation. MHRA describes the protection against endometrial hyperplasia and cancer. NICE recommendation 1.8.1 offers combined HRT when a uterus remains and oestrogen-only HRT after total hysterectomy. Confirm the surgery and any remaining tissue or relevant disease with the clinician. MHRA

Low-dose vaginal treatment has much lower systemic exposure, but the product and medical history still matter. MHRA’s August 2019 review summarised a meta-analysis including 108,647 breast-cancer cases. It found excess breast-cancer incidence with systemic HRT taken orally or through the skin, with some increased risk persisting more than 10 years after stopping. The same analysis found no evidence of increased breast-cancer risk from vaginal oestrogen for local symptoms. That population finding does not settle the separate question of recurrence after breast cancer. MHRA

Can local and systemic HRT be used together?

Yes, after assessment, if local symptoms remain despite systemic treatment. NICE explicitly includes people already using systemic HRT in its recommendation to offer vaginal oestrogen for menopause-associated genitourinary symptoms. That is not a general instruction to add a product: symptoms such as pain, itching, discharge or bleeding can have causes unrelated to menopause and may need examination.

Forum questions about whether any absorption makes a product systemic confuse a small bloodstream exposure with treatment intended to act throughout the body. NICE says the minimal absorption from low-dose vaginal oestrogen is unlikely to produce a significant whole-body effect. It also says symptoms often return after vaginal treatment stops, and that non-hormonal moisturisers or lubricants may be used alongside it. NICE

After breast cancer, NICE recommends non-hormonal moisturisers or lubricants first. Persistent symptoms may lead to consideration of vaginal oestrogen. Anyone receiving an aromatase inhibitor needs the breast-cancer specialist involved in identifying options. NICE says the effect of vaginal oestrogen on recurrence risk is unknown. For oestrogen receptor-positive disease, it also notes that a receptor-blocking treatment such as tamoxifen would reduce any potential effect from absorbed oestrogen. That distinction belongs in the specialist discussion, not a self-directed addition of hormones.

What changes the answer?

Symptoms, uterus status, medical history and the exact route determine the assessment.

  • The symptom pattern. Hot flushes, sleep disruption, vaginal discomfort, urinary symptoms and pain require different assessment; one label does not explain every symptom.
  • Whether the person has a uterus. This materially affects systemic oestrogen planning.
  • Personal and family history. Breast or other hormone-sensitive cancer, unexplained bleeding, blood clots, stroke, cardiovascular disease, migraine and liver disease may change the discussion.
  • Age and timing. Benefits and risks of systemic HRT vary with age, time since menopause and baseline health risks.
  • Route and ingredient. Oral and transdermal systemic HRT do not have identical risk profiles; oestrogen-only and combined HRT also differ.
  • Other medicines. In particular, people receiving endocrine treatment after breast cancer need specialist input before vaginal oestrogen is considered.

Which symptoms should not be self-labelled as menopause?

Bleeding, a breast lump or persistent pelvic pain needs assessment rather than being assumed to be menopause. Seek prompt review for postmenopausal bleeding, new or persistent treatment-related bleeding outside the pattern explained by the prescriber, or a concerning breast change. Seek emergency help for sudden chest pain, coughing blood, severe breathlessness, one-sided leg swelling, sudden weakness or speech difficulty. These symptoms do not establish that HRT is the cause, but they should not be managed by changing treatment without assessment.

NICE recommends assessing benefit and tolerability at 3 months, then annually unless ineffective treatment, side effects or adverse events need earlier review. Ongoing symptoms or side effects may need menopause expertise. HealthHub also asks vaginal estradiol users to report planned surgery or bed rest. NICE, HealthHub

At review, describe local and whole-body symptoms, whether the uterus and ovaries remain, unexplained bleeding, cancer or clot history, and every medicine. Ask whether the proposed product is local or systemic, what it is intended to improve, and which follow-up applies. Do not start, stop or combine hormone products based on their route name alone.

Sources